Q-omics provides the consensus-scored ENSAP2 profile across patient tissues and cancer cell-line models. ENSAP2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, ENSAP2 is differentially expressed in 6, with the highest sampling consensus in KICH. Additionally, ENSAP2 RNA expression shows 15,225 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SKCM, KICH, and ACC as cancer lineages where ENSAP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ENSAP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ENSAP2 survival associations across molecular data types. ENSAP2 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ENSAP2 RNA expression–survival associations across cancer types. High ENSAP2 expression shows unfavorable associations in ACC, LGG, BRCA and UVM, but favorable associations in SKCM and KIRC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for ENSAP2 RNA expression.
This table summarizes ENSAP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ENSAP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ENSAP2 shows lower tumor expression in KICH and THCA and higher tumor expression in BRCA, LIHC, CHOL and BLCA. The KICH box plot shows higher ENSAP2 RNA expression in normal versus tumor tissue (log2 FC = −0.333, t-test p = .003).
This table shows molecular features associated with ENSAP2 in patient tissues and cancer cell lines. In patient samples, ENSAP2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
